Scientific Advisory Board

Joseph C. Glorioso III, Ph.D.
Scientific Advisor

Joseph C. Glorioso III, Ph.D. - Oncorus Scientific Advisory Board

Joseph C. Glorioso III, Ph.D.

Scientific Advisor

Gaurav Sahay
Scientific Advisor

Gaurav Sahay  Assistant Professor in the College of Pharmacy at Oregon State University in Portland, Oregon

Gaurav Sahay

Scientific Advisor

Benjamin tenOever
Scientific Advisor

Benjamin tenOever - Oncorus Scientific Advisory Board

Benjamin tenOever

Scientific Advisor

Paola Grandi, Ph.D.
Scientific Advisor

Paola Grandi, Ph.D. - Oncorus Scientific Advisory Board

Paola Grandi, Ph.D.

Scientific Advisor

Joseph C. Glorioso III, Ph.D. - Oncorus Scientific Advisory Board

Joseph C. Glorioso III, Ph.D.
Scientific Advisor

Dr. Glorioso began his academic career at the University of Michigan Medical School where he became Professor of Microbiology and Immunology and Assistant Dean for Research and Graduate Studies. In 1989, Dr. Glorioso moved to the University of Pittsburgh School of Medicine to become the William S. McElroy Professor of Biochemistry and Chairman of the Department of Molecular Genetics and Biochemistry, a position he held until 2009. He continues to be a professor in this department.

Dr. Glorioso has established a 40-year history of research related to the basic pathobiology, immunology and genetics of herpes simplex virus (HSV). His contributions to the field include defining antiviral immune responses to infection, the genetics of viral pathogenesis and latency, and mechanisms of viral infection. Furthermore, he has been a pioneer in the design and application of HSV gene vectors for the treatment of nervous system diseases such as peripheral neuropathies, chronic pain, and brain tumors. He continues to be a worldwide leader in the HSV gene vector field through the creation of innovative gene vectors and the development of manufacturing methods for human clinical trials.

Dr. Glorioso has served as a member of the Recombinant DNA Advisory Committee (RAC), NIH (1994-1996); NIH Steering Committee of the National Gene Vector Laboratory (NGVL) (1995-2006); Member, NIH Steering Committee of the National Gene Vector Biorepository (2006- ); Founder, Member of the Board of Directors, Treasurer, Vice President, President, American Society of Gene and Cell Therapy (ASGCT); President, Association of Medical School Microbiology and Immunology Chairs (1999); National Steering Committee for the American Alliance for Cancer Gene Therapy (2006-) and Chair of ACGT Scientific Advisory Board (2014-). Dr. Glorioso was elected Fellow of the American Society of Microbiology (1991); Vectors/Pittsburgh – Man of the Year in Technology (1996); Elected to Who’s Who in America (1999); Elected Fellow of the American Association for the Advancement of Science (2003); 2007 Elected American Men and Woman of Science, Awarded the Paradigm Builder Lectureship by International Society of Neuro-virology (2010) and Human Gene Therapy: Gene Therapy Pioneer Award (2014).

Dr. Glorioso founded the Nature Journal Gene Therapy where he served as editor for 22 years and he is a member of the editorial board of Molecular Therapy. Dr. Glorioso co-founded several biotech companies that include Genvec Inc., Nuvovec srl and most recently Switch Bio, a neuromodulation company and Oncorus, Inc. a Cambridge based company dedicated to the use of oncolytic HSV for immunotherapy of cancer.

Gaurav Sahay - Assistant Professor in the College of Pharmacy at Oregon State University in Portland, Oregon

Gaurav Sahay
Assistant Professor in the College of Pharmacy at Oregon State University in Portland, Oregon

Gaurav Sahay is an Assistant Professor in the College of Pharmacy at Oregon State University in Portland, Oregon. Dr. Sahay works at interface of nanotechnology, cell biology and drug delivery. Gaurav completed his postdoctoral research with Prof (s). Robert Langer and Daniel Anderson at Koch Institute for Integrative Cancer Research at MIT and his PhD with Dr. Alexander Kabanov at the University of Nebraska Medical Center. He was trained in the use of nanomedicine for drug and gene delivery for treatment of cancer. Dr. Sahay’s lab has unlocked the molecular mechanisms involved in the intracellular delivery of nanoparticles and has used fundamental insights to design new materials that can effectively deliver nucleic acids like DNA, mRNA, siRNA, miRNA and sgRNA, to their subcellular targets. Sahay Lab has deployed non-viral vectors for treatment of rare genetic disorders like cystic fibrosis. He has over 30 publications in top tier journals including Nature Biotechnology, Nano Letters, Nature Nanotechnology, PNAS, Journal of Controlled Release, ACS Nano etc. Dr. Sahay is the winner of 2013 AAPS Postdoctoral Fellow Award, 2015 CRS T. Nagai Post Doc Award and New Investigator Awards from AACP and was the Chair of 2018 International Nanomedicine and Drug Delivery Symposium (nanoDDS2018). Sahay Lab has received funding from the NIH, Cystic Fibrosis Foundation, Medical Research Foundation of Oregon, OSU Foundation and several biotech companies.

Benjamin tenOever - Oncorus Scientific Advisory Board

Benjamin tenOever
Scientific Advisor

Benjamin tenOever completed his postdoctoral formation in Molecular Biology from Harvard University in 2007 after receiving his PhD in Medicine from McGill University in 2004. This training was subsequently applied to the study of host and pathogen interactions, with a focus on the molecular biology of virus infection. In August of 2007, Dr. tenOever joined the Icahn School of Medicine in New York as an Assistant Professor of Microbiology where he is now a Fishberg Professor of Medicine, and the Director of the Virus Engineering Center for Therapeutic and Research (VECToR). He is a 2008 Pew Scholar, a recipient of the 2009 Presidential Award in Science and Engineering, a 2010 recipient of the American Society of Microbiology Young Investigator Award, a 2011 Cozzarelli Prize winner, and he received the Burroughs Wellcome Award for his work regarding the pathogenesis of infectious disease. From 2012 to 2013, he was honored with Outstanding Young Investigator Awards from the American Society of Gene and Cell Therapy and the American Society of Virology. He was also named a finalist for the Vilcek Award for creative promise and served as a US Ambassador of Science in France as a Distinguished Chair of the Fulbright Commission in 2015/2016. Most recently he was honored with the Innovator Prize by the Pew Charitable Trust. The tenOever lab is interested in virus engineering and the development of new biological tools to ascertain the interplay between viruses and their hosts. More specifically, the lab focuses on what constitutes different cellular defense systems, how these systems have been shaped over time, and how viruses circumvent them and cause disease.

Paola Grandi, Ph.D. - Oncorus Scientific Advisory Board

Paola Grandi, Ph.D.
Scientific Advisor

Paola Grandi, Ph.D. is a scientific co-founder of Oncorus and is the Senior Director of Immunology and Virology.

Paola earned her PhD in Biochemistry from the University of Ferrara (Italy) in 2001 then moved to the U.S. to pursue her interests in oncolytic Herpes Simplex Virus-based vectors for treatment of recurrent malignant glioblastoma. After 4 years at Massachusetts General Hospital, Paola accepted a position as an Assistant Professor at the University of Pittsburgh where she developed miR-controlled oHSV vectors to tailor the replication of the virus to cancer cells.

Her research interests include studies to understand the development and progression of brain tumors emphasizing the role of the effect of the tumor microenvironment on oncolytic viral therapy. She has a long-standing interest in the molecular biology of Herpes Simplex Virus, mechanisms of virus replication and neuropathogenesis and virus host cells interactions that result in innate immune responses to infection.